Skip to main content
. 2026 Feb 19;18(2):258. doi: 10.3390/pharmaceutics18020258
IRM Indeterminate renal mass
ccRCC Clear-cell renal cell carcinoma
PET/CT Positron emission tomography/computed tomography
EAP Expanded access program
MRI Magnetic resonance imaging
EOT End of Treatment
SUV Standardized uptake value
CAIX Carbonic anhydrase IX